Incidence of Hepatocellular Carcinoma after Interferon Therapy in Patients with Chronic Hepatitis C.
-
- Onodera Hiroyoshi
- Department of Internal Medicine, Miyagi Cancer Center
-
- Ukai Katsuaki
- Department of Internal Medicine, Miyagi Cancer Center
-
- Suzuki Masaki
- Department of Internal Medicine, Miyagi Cancer Center
-
- Minami Yuko
- Department of Epidemiology, Miyagi Cancer Center
この論文をさがす
説明
We examined the effect of interferon (IFN) therapy for chronic active hepatitis (CAH) C in 207 patients by estimating the incidence of hepatocellular carcinoma (HCC) after IFN therapy using the person-years method. Statistical analysis was performed using the Mantel-Haenszel chi-square test. No HCC was detected in patients with normal serum alanine aminotransferase (ALT) levels after IFN therapy (response-effect group), and in patients with both normal serum ALT levels and hepatitis C virus (HCV)-RNA clearance after IFN therapy (complete-responder group). The incidence per 100,000 person-years in the patients with elevated serum ALT level after IFN therapy (other-effects group) and in the patients with positive HCV-RNA after IFN therapy (non-responder group) were 1968 and 1624, respectively. The incidence in control patients who did not achieve IFN therapy was 901. No statistically significant differences were observed between the other-effects group, non-responder group, and the control group. Our results so far suggest that normalization of the serum ALT levels and/or HCV clearance might reduce the incidence of HCC.
収録刊行物
-
- The Tohoku Journal of Experimental Medicine
-
The Tohoku Journal of Experimental Medicine 181 (2), 275-283, 1997
東北ジャーナル刊行会